Want to see GCTK full AI Analyst Report?
Top Page
GlucoTrack
(NASDAQ:GCTK)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.58
▲(101.03% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily weighed down by very weak financial performance (no meaningful revenue, large losses, persistent cash burn, and negative equity). Technicals provide only modest near-term support, while valuation is constrained by losses and no dividend. Corporate events are mixed, with supportive financing and development progress offset by significant Nasdaq delisting risk and potential dilution.
Positive Factors
Low leverage / minimal debt
The company carries minimal formal debt, which reduces near-term solvency pressure from creditors and preserves flexibility to prioritize R&D and clinical programs. Low leverage is a durable structural strength that eases interest obligations and supports longer runway from equity or convertible financing rounds.
Negative Factors
No meaningful revenue; persistent cash burn
The company reports essentially no revenue while consuming substantial cash (~-$16M TTM), creating ongoing funding needs. Persistent cash burn without commercial receipts is a structural weakness that raises dilution risk, constrains strategic optionality, and makes long-term R&D plans dependent on external financings.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / minimal debt
The company carries minimal formal debt, which reduces near-term solvency pressure from creditors and preserves flexibility to prioritize R&D and clinical programs. Low leverage is a durable structural strength that eases interest obligations and supports longer runway from equity or convertible financing rounds.
Read all positive factors
GlucoTrack (GCTK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.34M
Dividend YieldN/A
Average Volume (3M)2.54M
Price to Earnings (P/E)―
Beta (1Y)3.08
Revenue GrowthN/A
EPS Growth99.39%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-20.89
Shares Outstanding7,719,121
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit167.56
Enterprise Value/Ebitda0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GlucoTrack Business Overview & Revenue Model
Company Description
Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with...
How the Company Makes Money
null...
GlucoTrack Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
24
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -22.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -16.97M | -19.35M | -21.93M | -7.08M | -4.41M | -3.94M |
| Net Income | -16.89M | -19.39M | -22.60M | -7.10M | -4.43M | -4.07M |
Balance Sheet | ||||||
| Total Assets | 4.36M | 7.84M | 5.93M | 4.91M | 2.44M | 6.26M |
| Cash, Cash Equivalents and Short-Term Investments | 3.93M | 7.38M | 5.62M | 4.49M | 2.31M | 6.06M |
| Total Debt | 26.00K | 33.00K | 267.00K | 196.00K | 195.00K | 250.00K |
| Total Liabilities | 5.21M | 5.01M | 18.93M | 1.71M | 1.21M | 1.11M |
| Stockholders Equity | -851.00K | 2.83M | -13.00M | 3.20M | 1.23M | 5.16M |
Cash Flow | ||||||
| Free Cash Flow | -16.44M | -15.34M | -12.59M | -6.56M | -3.73M | -3.77M |
| Operating Cash Flow | -16.35M | -15.24M | -12.49M | -6.56M | -3.73M | -3.77M |
| Investing Cash Flow | -87.00K | -96.00K | -104.00K | 0.00 | 1.00K | -1.00K |
| Financing Cash Flow | 11.24M | 17.04M | 13.74M | 8.73M | 0.00 | 0.00 |
GlucoTrack Risk Analysis
GlucoTrack disclosed 36 risk factors in its most recent earnings report. GlucoTrack reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GlucoTrack Peers Comparison
UnderperformOutperform
Sector (51)
GCTK
GlucoTrack
0.40
-5.48
-93.16%
FEMY
Femasys
2.37
-13.14
-84.72%
WOK
WORK Medical Technology Group LTD
2.09
-791,097.85
-100.00%
GlucoTrack Corporate Events
Business Operations and StrategyPrivate Placements and Financing
GlucoTrack Secures New Financing to Support Growth
Positive
Aug 5, 2026
On August 4, 2026, Glucotrack entered into definitive agreements for approximately $5.5 million in follow-on and interim financing with institutional investors, combining a $3.5 million senior secured convertible bridge investment and a $2.0 milli...
Business Operations and StrategyProduct-Related Announcements
GlucoTrack Advances LT-100 to Single-Injection Development Strategy
Positive
Jul 30, 2026
On July 29, 2026, Lōkahi Therapeutics, a wholly owned subsidiary of Glucotrack, announced progress in the development strategy for LT-100, a therapeutic candidate whose historical administration required up to 15 intradermal injections per tr...
Business Operations and StrategyPrivate Placements and Financing
GlucoTrack Restructures Debt Through Equity-Linked Note Exchange
Neutral
Jul 27, 2026
On July 22, 2026, Glucotrack, Inc. entered into a new Exchange Agreement with an existing investor to restructure part of a promissory note originally issued on September 12, 2025, and subsequently reduced through prior exchange agreements in Apri...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
GlucoTrack Faces Multiple Nasdaq Deficiency Notices, Delisting Risk
Negative
May 15, 2026
On May 11, 2026, GlucoTrack received a Nasdaq Staff Determination letter stating that its shares no longer met the $1.00 minimum bid price requirement, prompting Nasdaq staff to move toward delisting the stock from The Nasdaq Capital Market. The c...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GlucoTrack Files IDE for Implantable Glucose Monitor
Positive
May 7, 2026
On May 7, 2026, Glucotrack announced that it has submitted an Investigational Device Exemption application to the U.S. Food and Drug Administration, seeking authorization to begin a U.S. clinical study of its fully implantable continuous blood glu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.